Cargando…

Challenges and advances in clinical applications of mesenchymal stromal cells

Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tian, Yuan, Zenan, Weng, Jianyu, Pei, Duanqing, Du, Xin, He, Chang, Lai, Peilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880217/
https://www.ncbi.nlm.nih.gov/pubmed/33579329
http://dx.doi.org/10.1186/s13045-021-01037-x
_version_ 1783650667327389696
author Zhou, Tian
Yuan, Zenan
Weng, Jianyu
Pei, Duanqing
Du, Xin
He, Chang
Lai, Peilong
author_facet Zhou, Tian
Yuan, Zenan
Weng, Jianyu
Pei, Duanqing
Du, Xin
He, Chang
Lai, Peilong
author_sort Zhou, Tian
collection PubMed
description Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease.
format Online
Article
Text
id pubmed-7880217
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78802172021-02-16 Challenges and advances in clinical applications of mesenchymal stromal cells Zhou, Tian Yuan, Zenan Weng, Jianyu Pei, Duanqing Du, Xin He, Chang Lai, Peilong J Hematol Oncol Review Mesenchymal stromal cells (MSCs), also known as mesenchymal stem cells, have been intensely investigated for clinical applications within the last decades. However, the majority of registered clinical trials applying MSC therapy for diverse human diseases have fallen short of expectations, despite the encouraging pre-clinical outcomes in varied animal disease models. This can be attributable to inconsistent criteria for MSCs identity across studies and their inherited heterogeneity. Nowadays, with the emergence of advanced biological techniques and substantial improvements in bio-engineered materials, strategies have been developed to overcome clinical challenges in MSC application. Here in this review, we will discuss the major challenges of MSC therapies in clinical application, the factors impacting the diversity of MSCs, the potential approaches that modify MSC products with the highest therapeutic potential, and finally the usage of MSCs for COVID-19 pandemic disease. BioMed Central 2021-02-12 /pmc/articles/PMC7880217/ /pubmed/33579329 http://dx.doi.org/10.1186/s13045-021-01037-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhou, Tian
Yuan, Zenan
Weng, Jianyu
Pei, Duanqing
Du, Xin
He, Chang
Lai, Peilong
Challenges and advances in clinical applications of mesenchymal stromal cells
title Challenges and advances in clinical applications of mesenchymal stromal cells
title_full Challenges and advances in clinical applications of mesenchymal stromal cells
title_fullStr Challenges and advances in clinical applications of mesenchymal stromal cells
title_full_unstemmed Challenges and advances in clinical applications of mesenchymal stromal cells
title_short Challenges and advances in clinical applications of mesenchymal stromal cells
title_sort challenges and advances in clinical applications of mesenchymal stromal cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880217/
https://www.ncbi.nlm.nih.gov/pubmed/33579329
http://dx.doi.org/10.1186/s13045-021-01037-x
work_keys_str_mv AT zhoutian challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT yuanzenan challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT wengjianyu challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT peiduanqing challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT duxin challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT hechang challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells
AT laipeilong challengesandadvancesinclinicalapplicationsofmesenchymalstromalcells